FINHUB Insights

RVTY · Q1 FY26 · Apr 5, 2026

Revvity Q1 FY26: where the revenue came from and where it went

Revvity Q1 FY26: revenue $0.7B (+7% year over year). Net profit $0B. Largest cohort Life Sciences $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 5, 2026
Reported
May 12, 2026 10-Q
Sankey diagram of Revvity's income statement for Q1 FY26: revenue of $0.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.7B +7% year over year
Gross profit$0.4B 55% margin
Operating profit$0.1B 11% margin
Net profit$0B 6% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Apr 5, 2026).
ItemValueShare of revenueYear over year
Revenue 0.7 100% +7%
Life Sciences 0.4 57% +6%
Diagnostics 0.3 43% +8%
Cost of revenue−0.343%
Gross profit0.455% margin−2pp
Research & development−0.18%+0pp
SG&A−0.236%−2pp
Operating profit0.111% margin+0pp
Net profit06%−1pp
Filing on EDGAR More quarters of RVTY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters